B Lau1, C L Overby, H S Wirtz2, E B Devine. 1. Department of Health Services, University of Washington , Seattle, WA. 2. Pharmaceutical Outcomes Research and Policy Program, University of Washington , Seattle, WA.
Abstract
BACKGROUND: Stage 2 Meaningful Use criteria require the use of clinical decision support systems (CDSS) on high priority health conditions to improve clinical quality measures. Although CDSS hold great promise, implementation has been fraught with challenges, evidence of their impact is mixed, and the optimal method of content delivery is unknown. OBJECTIVE: The authors investigated whether implementation of a simple clinical decision support (CDS) tool was associated with improved prescriber adherence to national medication-laboratory monitoring guidelines for safety (hepatic function, renal function, myalgias/rhabdomyolysis) and intermediate outcomes for antidiabetic (Hemoglobin A(1c); HbA(1c)) and antihyperlipidemic (low density lipoprotein; LDL) medications prescribed within a diabetes registry. METHODS: This was a retrospective observational study conducted in three phases of CDS implementation (2008-2009): pre-, transition-, and post-Prescriptions evaluated were ordered from an electronic health record within a multispecialty medical group. Adherence was evaluated within and without applying guideline-imposed time constraints. RESULTS: Forty-thousand prescriptions were ordered over three timeframes. For hepatic and renal function, the proportion of prescriptions for which labs were monitored at any time increased from 52% to 65% (p<0.001); those that met time guidelines, from 14% to 21% (p<0.001). Only 6% of required labs were drawn to monitor for myalgias/rhabdomyolysis, regardless of timeframe. Over 90% of safety labs were within normal limits. The proportion of labs monitored at any time for LDL increased from 56% to 64% (p<0.001); those that met time guidelines from 11% to 17% (p<0.001). The proportion of labs monitored at any time for HbA(1c) remained the same (72%); those that met time guidelines decreased from 45% to 41% (p<0.001). CONCLUSION: A simple CDS tool may be associated with improved adherence to guidelines. Efforts are needed to confirm findings and improve the timeliness of monitoring; investigations to optimize alerts should be ongoing.
BACKGROUND: Stage 2 Meaningful Use criteria require the use of clinical decision support systems (CDSS) on high priority health conditions to improve clinical quality measures. Although CDSS hold great promise, implementation has been fraught with challenges, evidence of their impact is mixed, and the optimal method of content delivery is unknown. OBJECTIVE: The authors investigated whether implementation of a simple clinical decision support (CDS) tool was associated with improved prescriber adherence to national medication-laboratory monitoring guidelines for safety (hepatic function, renal function, myalgias/rhabdomyolysis) and intermediate outcomes for antidiabetic (Hemoglobin A(1c); HbA(1c)) and antihyperlipidemic (low density lipoprotein; LDL) medications prescribed within a diabetes registry. METHODS: This was a retrospective observational study conducted in three phases of CDS implementation (2008-2009): pre-, transition-, and post-Prescriptions evaluated were ordered from an electronic health record within a multispecialty medical group. Adherence was evaluated within and without applying guideline-imposed time constraints. RESULTS: Forty-thousand prescriptions were ordered over three timeframes. For hepatic and renal function, the proportion of prescriptions for which labs were monitored at any time increased from 52% to 65% (p<0.001); those that met time guidelines, from 14% to 21% (p<0.001). Only 6% of required labs were drawn to monitor for myalgias/rhabdomyolysis, regardless of timeframe. Over 90% of safety labs were within normal limits. The proportion of labs monitored at any time for LDL increased from 56% to 64% (p<0.001); those that met time guidelines from 11% to 17% (p<0.001). The proportion of labs monitored at any time for HbA(1c) remained the same (72%); those that met time guidelines decreased from 45% to 41% (p<0.001). CONCLUSION: A simple CDS tool may be associated with improved adherence to guidelines. Efforts are needed to confirm findings and improve the timeliness of monitoring; investigations to optimize alerts should be ongoing.
Entities:
Keywords:
Adherence to guidelines; clinical decision support; clinical guidelines; meaningful use; medication laboratory test monitoring
Authors: David G Bundy; Jill A Marsteller; Albert W Wu; Lilly D Engineer; Sean M Berenholtz; A Harrison Caughey; David Silver; Jing Tian; Richard E Thompson; Marlene R Miller; Christoph U Lehmann Journal: Jt Comm J Qual Patient Saf Date: 2012-05
Authors: Emily Beth Devine; Ryan N Hansen; Jennifer L Wilson-Norton; N M Lawless; Albert W Fisk; David K Blough; Diane P Martin; Sean D Sullivan Journal: J Am Med Inform Assoc Date: 2010 Jan-Feb Impact factor: 4.497
Authors: Annette Moxey; Jane Robertson; David Newby; Isla Hains; Margaret Williamson; Sallie-Anne Pearson Journal: J Am Med Inform Assoc Date: 2010 Jan-Feb Impact factor: 4.497
Authors: Hardeep Singh; Eric J Thomas; Dean F Sittig; Lindsey Wilson; Donna Espadas; Myrna M Khan; Laura A Petersen Journal: Am J Med Date: 2010-03 Impact factor: 4.965
Authors: Mary Norine Walsh; Nancy M Albert; Anne B Curtis; Mihai Gheorghiade; J Thomas Heywood; Yang Liu; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Clyde W Yancy; Gregg C Fonarow Journal: Clin Cardiol Date: 2012-02-10 Impact factor: 2.882